46
3
1
7
Cat. No. | Product Name | ||
---|---|---|---|
L2192 | 抗胰腺癌化合物库 | 2238 compounds | |
2238 种与胰腺癌相关的化合物,可以用于高通量和高内涵筛选; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38502 |
IGF-1R inhibitor-2
|
||
IGF-1R inhibitor-2 (example 121) is a compound that inhibits the insulin-like growth factor-1 receptor (IGF-1R). By downregulating the IGF-1R, it has the potential to reverse the transformed phenotype of tumor cells and make them more susceptible to apoptosis. | |||
T2085 |
PQ401
IGF-1R Inhibitor II |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
PQ401 (IGF-1R Inhibitor II) 是一种IGF-IR 抑制剂。在 MCF-7 细胞中,它抑制 IGF-I 刺激的 IGF-IR 自磷酸化,可有效抑制 IGF-I 刺激的 MCF-7 细胞生长。它诱导 caspase 介导的细胞凋亡,有用于乳腺癌和其他对 IGF-I 敏感的癌症的研究潜力。 | |||
T8906 |
NBI-31772
NBI31772,NBI 31772 |
IGF-1R | Tyrosine Kinase/Adaptors |
NBI-31772 (NBI 31772) 是胰岛素样生长因子-1 结合蛋白 (IGFBP, Ki = 47 nM) 的有效抑制剂。 NBI-31772 可用于 IGF 反应性疾病的研究。 | |||
T2349 |
BMS-754807
|
Trk receptor; c-Met/HGFR; IGF-1R | Tyrosine Kinase/Adaptors |
BMS754807 是一种可逆的IGF-1R 抑制剂 (IC50:1.8 nM,Ki<2 nM),也是一种可逆的IR 抑制剂 (IC50:7 nM,Ki<2 nM)。它也抑制 Met (IC50:6 nM),RON (IC50:44 nM),TrkA (IC50:7 nM),TrkB (IC50:4 nM),AurA (IC50:9 nM) 和 AurB (IC50:25 nM) 的活性。 | |||
T17267 |
XL228
|
IGF-1R; Bcr-Abl; Src; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
XL228 是一种多靶点酪氨酸激酶抑制剂,对 Bcr-Abl、Aurora A、IGF-1R、Src 和 Lyn 的 IC50 分别为 5、3.1、1.6、6.1和 2 nM。 | |||
T6003 |
GSK1904529A
GSK 4529 |
Apoptosis; Raf; VEGFR; IGF-1R; Syk | Angiogenesis; Apoptosis; MAPK; Tyrosine Kinase/Adaptors |
GSK1904529A (GSK 4529) 是一种选择性,具有口服活性和 ATP 竞争性的胰岛素样生长因子 1 受体和胰岛素受体抑制剂,IC50值分别为 27 和 25 nM。它具有抗肿瘤活性。 | |||
T13564 |
AZ7550
|
MLK; FAK; EGFR; FLT; Tyrosine Kinases; PYK2; MNK; IGF-1R; ACK; BTK; ALK; Drug Metabolite | Angiogenesis; Cytoskeletal Signaling; JAK/STAT signaling; MAPK; Metabolism; Tyrosine Kinase/Adaptors |
AZ7550 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 | |||
T3079 |
GSK1838705A
|
IGF-1R; JNK; S6 Kinase; ALK | Angiogenesis; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
GSK1838705A 是一种高效的、可逆的IGF-IR (IC50:2.0 nM) 和胰岛素受体 (IC50:1.6 nM)抑制剂,也可抑制ALK (IC50:0.5 nM)。 | |||
T6017 |
Linsitinib
OSI-906,林西替尼 |
IGF-1R | Tyrosine Kinase/Adaptors |
Linsitinib (OSI-906) 是选择性的、有效的、具有口服活性的IGF-1和胰岛素受体(IR)的双重抑制剂,IC50分别为 35 和 75 nM。 | |||
T6080 |
NVP-AEW541
AEW541 |
FLT; Tyrosine Kinases; IGF-1R; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
NVP-AEW541 (AEW541) 是一种IGF-1R 抑制剂,IC50为 0.15 μM。它也抑制InsR,IC50为 0.14 μM。 | |||
T8496 |
MAZ51
|
Apoptosis; VEGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
MAZ51 是一种 VEGFR-3酪氨酸激酶的选择性抑制剂。它抑制 VEGF-C 诱导的 VEGFR-3 激活,而没有阻断 VEGF-C 介导的 VEGFR2 刺激。它阻止增殖并诱导多种肿瘤细胞凋亡,具有抗肿瘤活性。 | |||
T1791 |
Ceritinib
色瑞替尼,LDK378 |
Serine Protease; IGF-1R; ALK | Angiogenesis; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
Ceritinib (LDK378) 是一种选择性,具有口服活性的、ATP 竞争性的 ALK 酪氨酸激酶抑制剂,IC50=200 pM。 它还抑制 IGF-1R (IC50:8 nM),InsR (IC50:7 nM) 和 STK22D (IC50:23 nM)。它显示出良好抗肿瘤效力。 | |||
T10285 |
ALK inhibitor 1
|
FAK; IGF-1R; ALK | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
ALK inhibitor 1 是嘧啶类 ALK 的有效抑制剂。它是一种睾丸特异性丝氨酸/苏氨酸激酶 2 (TSSK2;IC50=31 nM) 和粘着斑激酶 (FAK;IC50=2 nM) 抑制剂。 | |||
T1918 |
NVP-TAE 226
TAE226 |
Apoptosis; FAK; c-Met/HGFR; PYK2; IGF-1R | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
NVP-TAE 226 (TAE226) 是一种具有 ATP 竞争性的双重FAK 和IGF-1R 抑制剂,IC50分别为 5.5 nM、140 nM。它还抑制Pyk2、胰岛素受体,IC50分为 3.5 nM、40 nM。 | |||
T6419 |
BMS-536924
HY-10262,胰岛素样生长因子-1 受体拮抗剂,BMS 536924,CS-0117 |
Apoptosis; FAK; MEK; IGF-1R; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; MAPK; Tyrosine Kinase/Adaptors |
BMS-536924 (BMS 536924) 是一种具有口服活性,竞争性和选择性的胰岛素样生长因子受体激酶和胰岛素受体抑制剂,IC50分别为 100 nM 和 73 nM。它具有抗癌活性。 | |||
T1791L |
Ceritinib dihydrochloride
LDK378 dihydrochloride,双盐酸盐色瑞替尼 |
IGF-1R; ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
Ceritinib dihydrochloride (LDK378 dihydrochloride) 是一种选择性的、口服具有活性的、ATP 竞争性的ALK 酪氨酸激酶抑制剂 (IC50:200 pM)。它还抑制IGF-1R (IC50:8 nM),InsR (IC50:7 nM) 和 STK22D (IC50:23 nM)。它显示出良好的抗肿瘤作用。 | |||
T13564L |
AZ7550 hydrochloride
AZ7550 hydrochloride (1421373-99-0 free base) |
EGFR; IGF-1R | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AZ7550 hydrochloride (AZ7550 hydrochloride ) 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 | |||
T6079 |
NVP-ADW742
ADW742,ADW,GSK 552602A |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
NVP-ADW742 (ADW) 是一种具有口服活性,选择性的IGF-1R 酪氨酸激酶抑制剂,IC50为 0.17 μM。它抑制胰岛素受体,IC50为 2.8 μM,在肿瘤细胞中诱导多效性抗增殖/促凋亡。 | |||
T1967 |
AZD-3463
ALK/IGF1R inhibitor |
Apoptosis; IGF-1R; ALK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Tyrosine Kinase/Adaptors |
AZD-3463 (ALK/IGF1R inhibitor) 是一种具有口服活性的ALK/IGF1R 抑制剂,对 ALK 作用的Ki 值为 0.75 nM。它可诱导神经母细胞瘤细胞凋亡和自噬。 | |||
T2693 |
AG1024
Tyrphostin AG 1024,Tyrphostin,AGS 200 |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
AG1024 (Tyrphostin) 是一种可逆的,竞争性和选择性的胰岛素样生长因子-1 受体抑制剂,IC50为 7 μM。它抑制胰岛素受体的磷酸化,IC50值为 57 μM。它诱导细胞凋亡并具有抗癌活性。 | |||
T4324 |
PQ401 hydrochloride (196868-63-0(free base))
|
IGF-1R | Tyrosine Kinase/Adaptors |
PQ401 hydrochloride (196868-63-0(free base)) 抑制 IGF-1R 结构域的自磷酸化,IC50 <1 μM。 | |||
T77624 |
WAY-270250
|
IGF-1R; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
WAY-270250 是一种 IGF-1R/SRC 抑制剂。 | |||
T11593 |
I-OMe-Tyrphostin AG 538
I-OMe-AG 538 |
IGF-1R; PI3K | PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
I-OMe-Tyrphostin AG 538是一种特异性 IGF-1R 抑制剂和 PI5P4Kα的 ATP 竞争性抑制剂(IC50:1 µM)。I-OMe-Tyrphostin AG 538可抑制 IGF-1R 介导的信号传导,并对营养缺乏的 PANC1细胞具有优先细胞毒性。 | |||
T76727 |
Teprotumumab
R 1507,HZN 001 |
TSH Receptor; IGF-1R | GPCR/G Protein; Tyrosine Kinase/Adaptors |
Teprotumumab 是一种阻断 IGF-1 受体 (IGF-1R) 的人单克隆抗体。Teprotumumab 与 IGF-1R 的细胞外 α-亚基结构域配体结合。Teprotumumab 抑制纤维细胞中的 TSH 和 IGF-1 作用。Teprotumumab 可降低 TSH 依赖性 IL-6 和 IL-8 的表达和 Akt 的磷酸化。Teprotumumab 可用于甲状腺相关眼病的研究。 | |||
T68405 |
KW-2450 free base
|
IGF-1R | Tyrosine Kinase/Adaptors |
KW-2450 free base 是一种 IGF-1R/IR和酪氨酸激酶多重抑制剂 具有抗肿瘤活性。KW-2450 free base 在小鼠 HT-29/GFP 结肠癌异种移植模型中显示出适度的生长抑制活性并抑制 IGF-1 诱导的信号转导。 | |||
T2341 |
KW-2449
KW2449 |
Apoptosis; FGFR; FLT; JAK; Bcr-Abl; Src; c-Kit; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
KW-2449是一种多靶点激酶抑制剂,对FLT3,ABL,ABLT315I 和极光激酶的IC50值分别为6.6,14,4 和 48 nM。 | |||
T5524 |
Aurora kinase inhibitor-3
Aurora Kinase Inhibitor III |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Aurora kinase inhibitor-3 (Aurora Kinase Inhibitor III) 是一种有效的,选择性 Aurora A 激酶抑制剂,IC50为 42 nM。 | |||
T4605 |
NT157
|
IGF-1R; STAT | JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI,主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。 | |||
T6289 |
Dovitinib
TKI258,多韦替尼,CHIR-258,度维替尼 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib (CHIR-258) 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂,具有抗肿瘤作用。 | |||
T6184 |
Orantinib
SU6668,TSU-68,NSC 702827 |
Apoptosis; VEGFR; FGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Orantinib (NSC 702827) 是一种多靶点受体酪氨酸激酶抑制剂,对 Flt-1、PDGFRβ和FGFR1的Ki 值分别为 2.1 μM、8 nM 和 1.2 μM。 | |||
T3570 |
SU4312
SU 4312,NSC 86429 |
VEGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
NSC-86429 是一种 (Z)-SU4312 (SU 4312) 和 (E)-SU4312 的外消旋体。其中(Z)-SU4312 能够抑制 PDGFR 和 FLK-1。(E)-SU4312 能够抑制 PDGFR, FLK-1, EGFR, HER-2, 和 IGF-1R。 | |||
T25123 |
AZ12253801
AZ 12253801,AZ-12253801 |
||
AZ12253801 is a type 1 insulin-like growth factor receptor (IGF-1R) inhibitor. | |||
T39257 |
Ugodotin
|
||
Ugodotin is an antibody-drug conjugate. Ugodotin can binds IGF-1R with antitumor activity. | |||
T77044 | Istiratumab | ||
Istiratumab (M-6495) 是靶向IGF-1R 和ErbB3的双特异性单克隆抗体。Istiratumab 通过蛋白酶体途径诱导IGF-1R 和 ErbB3 受体降解。Istiratumab 可用于癌症研究。 | |||
T78279 |
Cixutumumab
NSC742460,IMC-A12 |
||
Cixutumumab(IMC-A12)是一种高亲和力人源化抗IGF-1R单克隆抗体,能抑制配体依赖型受体活化及下游信号传导,并介导IGF-1R的内化与降解。该抗体显示出对多种癌症如肺癌、恶性肿瘤、白血病、非小细胞肺癌和前列腺癌的广泛抗肿瘤活性。 | |||
T70876 |
KW-2450 Tosylate
|
||
KW-2450 Tosylate is an orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential antineoplastic activity. IGF-1R/IR inhibitor KW-2450 Tosylate selectively binds to and inhibits the activities of IGF-1R and IR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-R1 and IR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in t... | |||
T76800 | Dalotuzumab | ||
Dalotuzumab (MK-0646) 是一种靶向IGF-1R 的重组人源化单克隆抗体 (IgG1 型)。Dalotuzumab 通过抑制IGF-1和IGF-2介导的肿瘤细胞增殖、IGF-1R 自体磷酸化和Akt 磷酸化而发挥作用。Dalotuzumab 还可诱导细胞凋亡和周期停滞。Dalotuzumab 与其他抗癌活性分子(如他汀类活性分子)共同使用,可增强 Dalotuzumab 的体外和体内抗肿瘤活性。 | |||
T77071 | Lonigutamab | ||
Lonigutamab (hz208F2-4) 是一种人源化抗 IGF-1R 单克隆抗体,可用于合成抗体-活性分子偶联物 (ADC)。 | |||
T68740 |
NVP-TAC544
|
||
NVP-TAC544 is a novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R. | |||
T70276 |
Roridin E
|
||
Roridin E inhibits the receptor tyrosine kinases FGFR3, IGF-1R, PDGFRβ, and TrkB (IC50s = 0.4, 0.4, 1.4, and 1 μM, respectively) and induces cytotoxicity in multiple breast cancer cell lines (IC50s = 0.02-0.05 nM). It also inhibits proliferation in a panel of additional cancer cell lines (IC50s = <0.01 μM). | |||
T76759 | Robatumumab | ||
Robatumumab (Sch 717454) 为针对人胰岛素样生长因子 1 受体(anti-humanIGF-1R)的抗体,展现出抗肿瘤及阻止癌细胞增殖的作用,适用于骨肉瘤与尤文肉瘤的研究。 | |||
T3621 |
Brigatinib
布格替尼,AP-26113 |
EGFR; FLT; ROS; IGF-1R; ALK | Angiogenesis; Immunology/Inflammation; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Brigatinib (AP-26113) 是一种有效,选择性的ALK 抑制剂 (IC50:0.6 nM)。 | |||
T83911 |
CYY292
|
||
CYY292是一种针对PDGFRα、PDGFRβ、FGFR1、-2和-3的抑制剂(IC50分别为5.35、4.6、28、28和78 nM)。该化合物对这些激酶的选择性高于FGFR4(IC50 > 1,000 nM),但也能抑制c-Kit、VEGFR2、VEGFR1和胰岛素样生长因子1受体(IGF-1R;IC50分别为67、33、36和75 nM),以及EGFR、布鲁顿酪氨酸激酶(BTK)、细胞周期依赖性激酶4(Cdk4)/cyclin D3和MET(IC50分别为128、198、214和396 nM)。CYY292抑制MG-63、U2OS、MNNG/HOS和Saos-2骨肉瘤细胞的增殖(IC50分别为0.84、0.76、1.36和0.72 µM)。在0.3和0.5 µM的浓度下,它抑制U87MG和LN-229胶质母细胞瘤细胞的迁移和侵袭。CYY292(30 mg/kg)在U87MG原位小鼠异种移植模型中降低肿瘤体积并增加生存率。 | |||
T13564L2 |
AZ7550 trimesylate salt
AZ7550 Mesylate,AZ7550 trimesylate salt (1421373-99-0 free base) |
MLK | MAPK |
AZ7550 trimesylate salt (AZ7550 Mesylate) 是奥希替尼的活性代谢产物,AZ7550 trimesylate salt 抑制 IGF1R 活性,可用于研究非小细胞肺癌。 | |||
T11654 | Indirubin Derivative E804 | Others | Others |
Indirubin Derivative E804 is an effective inhibitor of IGF1R, which has an IC50 value of 0.65. | |||
T12102 |
Mps1-IN-1
|
Others | Others |
Mps1-IN-1 is a potent, selective and ATP-competitive inhibitor of Mps1 kinase (IC50 : 367 nM ) |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6S1487 |
Ginsenoside Rg5
人参皂苷Rg5,人参皂甙 Rg5 |
NF-κB; COX; IGF-1R | Immunology/Inflammation; Neuroscience; NF-κB; Tyrosine Kinase/Adaptors |
Ginsenoside Rg5 是红参的主要成分,可阻断IGF-1与其受体的结合,IC50约为90 nM。它还通过抑制NF-κB p65的 DNA 结合活性来抑制COX-2的 mRNA 表达。它可促进血管生成和改善高血压,具有抗炎和治疗阿尔茨海默病的潜力。 | |||
T6943 |
Picropodophyllin
AXL1717,苦鬼臼脂素,Picropodophyllin (PPP),Picropodophyllotoxin,PPP,苦鬼臼毒素 |
Apoptosis; IGF-1R | Apoptosis; Tyrosine Kinase/Adaptors |
Picropodophyllin (Picropodophyllin (PPP)) 是一种选择性的胰岛素样生长因子-1受体抑制剂,IC50为1 nM。 | |||
T3923 |
Calycosin
Cyclosin,3'-Hydroxyformononetin,异黄酮,毛异黄酮 |
Apoptosis; Tyrosinase | Apoptosis; Proteases/Proteasome |
Calycosin (Cyclosin) 是一抗氧化和抗炎症活性天然产物。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00456 |
IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated
CD221,MGC142172,IGFIR,IGFR,MGC18216,JTK13,... |
Human | HEK293 Cells |
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated is expressed in ... | |||
TMPK-00455 |
IGF1R/CD221 Protein, Human, Recombinant (His & Avi)
MGC142172,IGF-I receptor,IGF-I R,IGF |
Human | HEK293 Cells |
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells wi... | |||
TMPK-00658 |
IGF1R/CD221 Protein, Cynomolgus, Recombinant (His)
CD221,IGFR,IGF1R,MGC142172,MGC182... |
Cynomolgus | HEK293 Cells |
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells wit... | |||
TMPY-06195 |
IGF1R/CD221 Protein, Mouse, Recombinant (His)
insulin-like growth factor 1 receptor,CD221,IGF- |
Mouse | HEK293 Cells |
IGF1R/CD221 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 105.2 kDa and the accession number is E9QNX9. | |||
TMPY-00150 |
IGF2/IGF-II Protein, Human, Recombinant
PP9974,胰岛素样生长因子,C11orf43,IGF-II,insulin-like growth... |
Human | P. pastoris (Yeast) |
Insulin-like growth factor 2 (IGF-2/IGF-II) is a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumor, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. IGF-2/IGF-II is a mediator of prolactin-induced alveologenesis; prolactin, IGF-2, and cyclin D1, all of which are overexpressed in br... | |||
TMPK-00083 |
IGF1/IGF-I Protein, Human, Recombinant (hFc)
IGF1A,胰岛素样生长因子,IBP1,IGF-I,MGF |
Human | HEK293 Cells |
The insulin family consists of insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), their receptors (IR, IGF-1R and IGF-2R), and their binding proteins.Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. | |||
TMPK-00061 |
IGF2/IGF-II Protein, Human, Recombinant (hFc)
IGF2,IGF-II,PP1446,Somatomedin A,Somatomed... |
Human | HEK293 Cells |
The insulin family consists of insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), their receptors (IR, IGF-1R and IGF-2R), and their binding proteins. All three ligands are involved in cell proliferation, apoptosis, protein synthesis and metabolism due to their homologous sequences and structural similarities. Insulin-like growth factor 2, a member of the insulin family, plays an important role in embryonic development, metabolic disorders, and tumorigenesis by ... |